Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents (Q34214392)

31 July 2017

title

Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents (English)

1 reference

31 July 2017

1 reference

Nelson WG

1

1 reference

31 July 2017

Wilding G

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

57

1 reference

31 July 2017

issue

4 Suppl 1

1 reference

31 July 2017

page(s)

56-63

1 reference

Epidemiologic evidence regarding predisposing factors to prostate cancer

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Case-control study of diet and prostate cancer in China

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Diet and prostatic cancer: a case-control study in Hawaii

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

A prospective study of dietary fat and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Phytoestrogen intake and prostate cancer: a case-control study using a new database

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Molecular advances in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

The human genome project and the future of medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Cancer genome anatomy project set for take-off.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Design of the Prostate Cancer Prevention Trial (PCPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

p21ras is modified by a farnesyl isoprenoid

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Carboxyl methylation and farnesylation of transducin gamma-subunit synergistically enhance its coupling with metarhodopsin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

In vivo farnesylation of rat rhodopsin kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900942-0

7 January 2021

10.1016/S0090-4295(00)00942-0

Identifiers

DOI

1 reference

31 July 2017

1 reference